Track market-moving stories before they get noisy

Posted by Defense World Staff on Jul 25th, 2026

Bank of Nova Scotia lessened its stake in shares of Danaher Corporation (NYSE:DHR – Free Report) by 1.6% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 202,353 shares of the conglomerate’s stock after selling 3,275 shares during the period. Bank of Nova Scotia’s holdings in Danaher were worth $38,366,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Norges Bank bought a new position in shares of Danaher in the fourth quarter worth about $2,177,106,000. Viking Global Investors LP grew its holdings in Danaher by 543.9% during the 2nd quarter. Viking Global Investors LP now owns 2,907,515 shares of the conglomerate’s stock valued at $574,351,000 after buying an additional 2,455,994 shares in the last quarter. Massachusetts Financial Services Co. MA raised its position in shares of Danaher by 104.7% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,333,056 shares of the conglomerate’s stock valued at $991,923,000 after buying an additional 2,216,789 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Danaher by 11.2% during the fourth quarter. Wellington Management Group LLP now owns 15,076,796 shares of the conglomerate’s stock valued at $3,451,380,000 after buying an additional 1,517,904 shares during the last quarter. Finally, Capital International Investors lifted its holdings in shares of Danaher by 8.9% in the fourth quarter. Capital International Investors now owns 18,246,008 shares of the conglomerate’s stock worth $4,177,386,000 after buying an additional 1,487,768 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Down 0.3% NYSE DHR opened at $191.87 on Friday. The company has a quick ratio of 1.52, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. Danaher Corporation has a 52 week low of $160.93 and a 52 week high of $242.80. The firm has a market capitalization of $134.88 billion, a price-to-earnings ratio of 34.08, a PEG ratio of 2.40 and a beta of 0.79. The company has a fifty day moving average of $185.64 and a two-hundred day moving average of $197.04.

Danaher (NYSE:DHR – Get Free Report) last released its earnings results on Tuesday, July 21st. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The firm had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. During the same quarter last year, the business earned $0.77 EPS. The business’s revenue was up 5.5% on a year-over-year basis. On average, analysts predict that Danaher Corporation will post 8.53 earnings per share for the current year.

Danaher Announces Dividend The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Friday, June 26th will be paid a $0.40 dividend. The ex-dividend date of this dividend is Friday, June 26th. This represents a $1.60 annualized dividend and a yield of 0.8%. Danaher’s dividend payout ratio (DPR) is presently 28.42%.

Key Headlines Impacting Danaher Here are the key news stories impacting Danaher this week:

Positive Sentiment: J.P. Morgan reiterated a Buy rating on Danaher, which may help support investor confidence after the post-earnings pullback. J.P. Morgan Keeps Their Buy Rating on Danaher (DHR) Positive Sentiment: Several articles argue Danaher’s recent slump looks like an overreaction and could be a buying opportunity, suggesting the stock may recover if investors refocus on its long-term fundamentals. Here’s Why the Slump in Danaher Stock This Week Looks Like a Buying Opportunity Positive Sentiment: Danaher’s quarterly results beat estimates, with EPS of $1.94 versus $1.85 expected and revenue of $6.27 billion above forecasts, which supports the case that core business performance remains solid. The ‘Standout Performance’ That Could Save Thermo Fisher, Danaher And Others Neutral Sentiment: Billionaire investor Dan Loeb reduced his Danaher stake in Q1 2026, adding to sentiment pressure around life sciences tools stocks, though it does not change Danaher’s operating results. Billionaire Investor Dumps Thermo Fisher, Cuts Danaher As He Pares Life Sciences Tools Bets Neutral Sentiment: Danaher saw unusually heavy put option activity, signaling traders are hedging against more downside in the near term. Don’t Quit on Danaher Stock After Horrific Earnings Reaction Analysts Set New Price Targets Several equities analysts recently weighed in on the stock. Argus reduced their price target on shares of Danaher from $265.00 to $230.00 and set a “buy” rating on the stock in a report on Friday, April 24th. Wells Fargo & Company cut their price objective on Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a research report on Wednesday. The Goldman Sachs Group reduced their target price on Danaher from $265.00 to $230.00 and set a “buy” rating on the stock in a report on Monday, April 13th. Robert W. Baird dropped their price target on Danaher from $251.00 to $249.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Finally, DZ Bank initiated coverage on Danaher in a report on Wednesday, June 3rd. They set a “buy” rating and a $210.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and a consensus target price of $228.91.

Get Our Latest Report on Danaher

Danaher Company Profile (Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.

See Also Five stocks we like better than Danaher AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Plugging In: How Kinder Morgan Powers Up Profits Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR – Free Report).

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEBank of Nova Scotia Boosts Stake in American International Group, Inc. $AIG

NEXT HEADLINE »Bank of Nova Scotia Has $35.59 Million Stake in Rubrik, Inc. $RBRK

Danaher (DHR - Free Report) closed the last trading session at $179.01, gaining 0% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $237 indicates a 32.4% upside potential.

The average comprises 23 short-term price targets ranging from a low of $200.00 to a high of $310.00, with a standard deviation of $25.98. While the lowest estimate indicates an increase of 11.7% from the current price level, the most optimistic estimate points to an 73.2% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.

While the consensus price target is a much-coveted metric for investors, solely banking on this metric to make an investment decision may not be wise at all. That's because the ability and unbiasedness of analysts in setting price targets have long been questionable.

But, for DHR, an impressive average price target is not the only indicator of a potential upside. Strong agreement among analysts about the company's ability to report better earnings than they predicted earlier strengthens this view. While a positive trend in earnings estimate revisions doesn't gauge how much a stock could gain, it has proven to be powerful in predicting an upside.

Price, Consensus and EPS Surprise

Here's What You Should Know About Analysts' Price TargetsAccording to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading.

While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business to economic and industry issues, many of them tend to set overly optimistic price targets. Are you wondering why?

They usually do that to drum up interest in shares of companies that their firms either have existing business relationships with or are looking to be associated with. In other words, business incentives of firms covering a stock often result in inflated price targets set by analysts.

However, a tight clustering of price targets, which is represented by a low standard deviation, indicates that analysts have a high degree of agreement about the direction and magnitude of a stock's price movement. While that doesn't necessarily mean the stock will hit the average price target, it could be a good starting point for further research aimed at identifying the potential fundamental driving forces.

That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treated with a high degree of skepticism.

Why DHR Could Witness a Solid UpsideAnalysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason to expect an upside in the stock. That's because empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

Over the last 30 days, the Zacks Consensus Estimate for the current year has increased 0.6%, as two estimates have moved higher while one has gone lower.

Moreover, DHR currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than 4,000 stocks that we rank based on four factors related to earnings estimates. Given an impressive externally-audited track record, this is a more conclusive indication of the stock's potential upside in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Therefore, while the consensus price target may not be a reliable indicator of how much DHR could gain, the direction of price movement it implies does appear to be a good guide.

Posted by Defense World Staff on Jul 22nd, 2026

Andra AP fonden raised its holdings in shares of Danaher Corporation (NYSE:DHR – Free Report) by 648.7% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 76,642 shares of the conglomerate’s stock after buying an additional 66,405 shares during the period. Andra AP fonden’s holdings in Danaher were worth $14,531,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in DHR. Sivia Capital Partners LLC boosted its stake in shares of Danaher by 6.3% during the 2nd quarter. Sivia Capital Partners LLC now owns 2,009 shares of the conglomerate’s stock worth $397,000 after acquiring an additional 119 shares in the last quarter. First Trust Advisors LP lifted its holdings in shares of Danaher by 34.5% during the second quarter. First Trust Advisors LP now owns 55,418 shares of the conglomerate’s stock valued at $10,947,000 after purchasing an additional 14,217 shares during the last quarter. Main Street Financial Solutions LLC lifted its holdings in shares of Danaher by 40.2% during the second quarter. Main Street Financial Solutions LLC now owns 3,088 shares of the conglomerate’s stock valued at $610,000 after purchasing an additional 886 shares during the last quarter. Ieq Capital LLC boosted its position in shares of Danaher by 64.2% in the 2nd quarter. Ieq Capital LLC now owns 75,714 shares of the conglomerate’s stock valued at $14,957,000 after purchasing an additional 29,592 shares during the period. Finally, HUB Investment Partners LLC boosted its position in shares of Danaher by 30.7% in the 2nd quarter. HUB Investment Partners LLC now owns 1,383 shares of the conglomerate’s stock valued at $273,000 after purchasing an additional 325 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analyst Ratings Changes Several research analysts have commented on DHR shares. Evercore reiterated an “outperform” rating and issued a $230.00 target price on shares of Danaher in a report on Monday, July 6th. Barclays reduced their price target on shares of Danaher from $250.00 to $230.00 and set an “overweight” rating for the company in a research report on Tuesday, April 14th. The Goldman Sachs Group decreased their price objective on shares of Danaher from $265.00 to $230.00 and set a “buy” rating for the company in a research note on Monday, April 13th. Rothschild & Co Redburn set a $205.00 price objective on shares of Danaher in a research report on Friday, April 17th. Finally, Argus cut their target price on shares of Danaher from $265.00 to $230.00 and set a “buy” rating on the stock in a research note on Friday, April 24th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $231.64.

Check Out Our Latest Stock Analysis on Danaher

Danaher News Summary Here are the key news stories impacting Danaher this week:

Positive Sentiment: Danaher posted Q2 adjusted EPS of $1.94, above the $1.84 consensus, and revenue of about $6.26 billion to $6.3 billion, also ahead of estimates. Danaher Reports Second Quarter 2026 Results Positive Sentiment: Management raised full-year adjusted EPS guidance, showing confidence in profitability despite the softer sales backdrop. Danaher Corp (DHR) Q2 2026 Earnings Call Highlights Neutral Sentiment: Life Sciences was a bright spot, with stronger sales growth, but bioprocessing revenue came in weaker than expected and was cited as a drag on sentiment. Reuters: Danaher’s revenue outlook cut, biotech miss overshadow profit forecast raise Negative Sentiment: Investors reacted negatively to the reduced core revenue growth outlook and cautious near-term guidance, which outweighed the earnings beat and led to the stock decline. Danaher stock slips despite Q2 earnings beat, raised guidance Negative Sentiment: Analysts also highlighted “surprisingly soft” bioprocessing sales, reinforcing concerns that growth may slow more than expected. Danaher Plummets After One Segment Comes In ‘Surprisingly Soft’ Danaher Trading Down 11.0% Danaher stock opened at $179.01 on Wednesday. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.87 and a quick ratio of 1.52. The company has a market capitalization of $126.70 billion, a price-to-earnings ratio of 34.62, a PEG ratio of 2.48 and a beta of 0.79. Danaher Corporation has a one year low of $160.93 and a one year high of $242.80. The company’s fifty day moving average price is $184.22 and its two-hundred day moving average price is $197.69.

Danaher (NYSE:DHR – Get Free Report) last announced its quarterly earnings results on Tuesday, July 21st. The conglomerate reported $1.94 earnings per share for the quarter, topping analysts’ consensus estimates of $1.84 by $0.10. The company had revenue of $6.26 billion during the quarter, compared to analysts’ expectations of $6.11 billion. Danaher had a return on equity of 10.91% and a net margin of 14.89%.The business’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.77 earnings per share. On average, analysts forecast that Danaher Corporation will post 8.45 earnings per share for the current fiscal year.

Danaher Dividend Announcement The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Friday, June 26th will be paid a $0.40 dividend. The ex-dividend date is Friday, June 26th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.9%. Danaher’s payout ratio is presently 30.95%.

Danaher Profile (Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.

Featured Stories Five stocks we like better than Danaher Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAndra AP fonden Has $13.79 Million Stake in West Pharmaceutical Services, Inc. $WST

NEXT HEADLINE »California Public Employees Retirement System Buys 33,638 Shares of Southern Copper Corporation $SCCO

4.64K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

The Often-Missed Corner of Healthcare That Wall Street Is LovingDanaher NYSE: DHR reported better-than-expected second-quarter 2026 results, with management citing accelerating core revenue growth, stronger life sciences demand and benefits from productivity initiatives, while also addressing investor concerns over delayed bioprocessing shipments.

President and Chief Executive Officer Rainer M. Blair said the company delivered “better-than-expected revenue, earnings, and cash flow” in the quarter. He said core growth improved from the first quarter, supported by commercial execution, recent product launches and recovering end markets.

Get Danaher alerts:

An AI Play Hiding in Plain Sight: A Look at Johnson ControlsDanaher reported second-quarter sales of $6.3 billion. Core revenue increased 3% year over year, while core growth excluding respiratory testing revenue rose 4.5%, representing a 150-basis-point acceleration from the first quarter. Adjusted diluted net earnings per common share were $1.94, up about 8% year over year. The company generated $1.3 billion in free cash flow during the quarter and $2.4 billion in the first half, with year-to-date free cash flow to net income conversion of 124%.

Blair said demand from large pharma and biopharma customers remained healthy, biotech funding improved, academic and government markets largely stabilized, and clinical and applied markets continued to be sources of strength. Core revenue in high-growth markets increased more than 10%, including mid-single-digit growth in China.

Life Sciences Posts Strongest Quarter in Several Years 3 Stocks Offering Strong Value and StabilityDanaher’s Life Sciences segment was a standout in the quarter, with core revenue increasing 5.5%. Blair said the segment delivered its strongest quarter in several years, helped by improving customer demand and product innovation.

Pall’s applied filtration business grew approximately 10%, led by strength in microelectronics. Chief Financial Officer Matt Gugino said microelectronics grew faster than the overall Pall business, while energy and aerospace also contributed. Blair said Pall’s filtration solutions are mission-critical across the semiconductor manufacturing workflow and noted the company is starting up a new plant in Singapore.

Danaher’s life sciences instrument businesses grew mid-single digits, with solid growth at Beckman Life Sciences, Leica Microsystems and SCIEX. Blair highlighted Beckman Life Sciences’ growth in automation, saying the business is positioned to benefit as customers invest in autonomous labs and AI-enabled drug discovery.

Life sciences consumables collectively grew low single digits. Integrated DNA Technologies rose on demand for minimal residual disease testing solutions, while Abcam delivered its best quarter since Danaher acquired it. Blair said Abcam benefited from improved academic market stability, stronger commercial execution and progress expanding into biopharma and diagnostics end markets.

Bioprocessing Growth Slowed by Customer Timing The Biotechnology segment reported core revenue growth of 2.5%. Within the segment, discovery and medical grew mid-single digits, while bioprocessing grew low single digits across both consumables and equipment.

Bioprocessing was a major focus of the question-and-answer portion of the call after Danaher lowered its outlook for the business. Blair said several large chromatography resin shipments planned primarily for the second and third quarters were delayed at customer request due to production schedule changes and site readiness issues. He said the affected shipments were tied primarily to commercial programs where Danaher is “specced into” production.

Gugino said the second-quarter impact was about 500 basis points to bioprocessing growth, or roughly $50 million to $60 million. For the full year, he said a little more than $100 million shifted out of 2026 and into next year, representing a couple hundred basis points of growth impact. Danaher is not assuming those shipments return in the fourth quarter, although Gugino said there is some chance they could.

Management emphasized that underlying demand remained strong. Blair said consumables and equipment orders both grew mid-teens in the quarter, and he characterized the delays as concentrated among a few large commercial customers rather than a broad-based change in demand. He also said inventory levels across the market are “quite a bit lower” than in prior years, reflecting shorter lead times and continued robust demand for biologic therapies.

Blair said Danaher continues to believe Cytiva’s bioprocessing franchise has a high-single-digit long-term growth outlook. He also said the company is in the early stages of a multiyear capital expenditure cycle tied to biologics demand and reshoring activity.

Diagnostics Growth Led by Non-Respiratory Revenue The Diagnostics segment reported 2% core revenue growth. Excluding respiratory testing revenue, core growth was 5%.

Clinical diagnostics businesses grew mid-single digits, including high-single-digit growth outside China. Leica Biosystems and Radiometer collectively grew high single digits, supported by instruments and consumables. Beckman Coulter Diagnostics grew mid-single digits globally, with another quarter of immunoassay revenue and installed base growth.

Blair said declines in China at Beckman Coulter began to moderate as pricing stabilized and volumes improved. Gugino later said China policy headwinds are starting to lessen, contributing to expected improvement in the back half of the year.

In molecular diagnostics, Cepheid’s non-respiratory core revenue increased low double digits, led by hospital-acquired infection and sexual health assays. Blair said growth was supported by menu expansion, including the Multiplex GI panel, and account wins with large hospital networks. Respiratory revenue was in line with expectations but down year over year due to lower seasonal infection rates.

Masimo Closed Early, StatLab Deal Pending Danaher closed its acquisition of Masimo in early June, earlier than initially expected. Blair said the business is expected to be immediately accretive strategically and to adjusted earnings per share. He said Masimo delivered high-single-digit revenue growth in the first half and had already received FDA 510(k) clearance for an AI-enabled opioid-induced respiratory depression detection solution.

Gugino said the earlier Masimo closing contributed about $0.07 to $0.08 to the updated earnings outlook. He said Masimo’s core growth was high single digits and “even a little bit better than we expected.”

Danaher also announced that Leica Biosystems plans to acquire StatLab, a manufacturer of consumables used in anatomical pathology workflows. Blair said StatLab generated about $250 million in 2025 revenue, with more than 85% recurring revenue. Danaher expects the business to grow high single digits over the long term and be accretive to adjusted EPS in the first full year of ownership. The transaction is expected to close by the end of 2026, subject to customary conditions and regulatory approvals.

During the quarter, Danaher also repurchased 5 million shares of common stock for about $900 million.

Guidance Raised for 2026 Danaher raised its full-year adjusted diluted EPS guidance to a range of $8.45 to $8.60, up from its previous outlook of $8.35 to $8.55. The company continues to expect full-year 2026 core revenue growth of 3% to 4%.

For the third quarter, Danaher expects revenue growth of approximately 2% to 3%, including a roughly 250-basis-point headwind from respiratory testing. Excluding respiratory, the company expects core growth of about 5% in the third quarter. Management said it expects to exit the fourth quarter at a mid-single-digit core revenue growth rate as respiratory headwinds fade.

Gugino said the updated full-year outlook reflects stronger anticipated life sciences growth, offset by a more conservative bioprocessing outlook due to the customer-driven timing shifts. He said the midpoint of the new EPS range implies nearly 10% EPS growth for the year.

About Danaher (NYSE:DHR)Danaher Corporation NYSE: DHR is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher's portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Danaher Right Now?Before you consider Danaher, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.

While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Danaher Corporation (DHR) Q2 2026 Earnings Call July 21, 2026 8:00 AM EDT

Company Participants

Rachel Vatnsdal Olson - Vice President of Investor Relations
Rainer Blair - President, CEO & Director
Matthew Gugino - Executive VP & CFO

Conference Call Participants

Michael Ryskin - BofA Securities, Research Division
Tycho Peterson - Jefferies LLC, Research Division
Dan Leonard - RBC Capital Markets, Research Division
Scott Davis - Melius Research LLC
Jack Meehan
Vijay Kumar - Evercore ISI Institutional Equities, Research Division
Daniel Brennan - TD Cowen, Research Division
Casey Woodring - JPMorgan Chase & Co, Research Division
Patrick Donnelly - Citigroup Inc., Research Division

Presentation

Operator

My name is Chelsea, and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to the Danaher Corporation's Second Quarter 2026 Earnings Results Conference Call. [Operator Instructions]

I will now turn the call over to Ms. Rachel Vatnsdal, Vice President of Investor Relations. Ms. Vatnsdal, you may begin your conference.

Rachel Vatnsdal Olson
Vice President of Investor Relations

Good morning, everyone, and thanks for joining us on the call. With us today are Rainer Blair, our President and Chief Executive Officer; and Matt Gugino, our Executive Vice President and Chief Financial Officer. I'd like to point out that our earnings release, quarterly report on Form 10-Q, the slide presentation supplementing today's call, the reconciliations and other information required by SEC Regulation G relating to any non-GAAP financial measures provided during the call and a note containing details of historical and anticipated future financial performance are all available on the Investors section of our website, www.danaher.com, under the heading Quarterly Earnings.

The audio portion of this call will be archived on the Investors section of our website later today under the heading Events and Presentations and will remain archived until our next quarterly call. A dial-in replay

U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining more than 1% on Tuesday.

Shares of Danaher Corp (NYSE:DHR) fell sharply in pre-market trading following second-quarter results.

Danaher posted second-quarter adjusted EPS of $1.94, beating market estimates of $1.83. The company’s sales reached $6.265 billion topping estimates of $6.102 billion.

Danaher shares dipped 10.1% to $180.76 in pre-market trading.

Here are some other stocks moving lower in pre-market trading.

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

CompaniesJuly 21 (Reuters) - Danaher (DHR.N), opens new tab raised its annual profit forecast on Tuesday, but shares fell nearly 12% in premarket trading after the life sciences firm ​trimmed its core revenue growth outlook and reported weaker-than-expected revenue ‌in its biotechnology business.

The results come as conditions are improving for the life sciences tools industry as biotechs and pharmaceutical companies increase spending on research and manufacturing ​programs after a prolonged post-pandemic slowdown.

Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.

However, the outlook is "mixed and not ​consistent with a re-acceleration narrative," RBC Capital Markets analysts ⁠said.

Danaher's results also weighed on peers; Agilent Technologies (A.N), opens new tab fell 1.7% before the bell, while Thermo Fisher Scientific (TMO.N), opens new tab, ​Revvity (RVTY.N), opens new tab and Illumina (ILMN.O), opens new tab declined 2% to 4%.

Danaher lowered the upper end of its ​core revenue growth outlook range for the year to 4% from 6% to reflect the impact of weaker respiratory testing revenue, while maintaining the lower end at 3%.

Revenue ​from its biotechnology unit rose 4% to $1.92 billion, below estimates of $1.97 ​billion, according to data compiled by LSEG.

Danaher said underlying demand for bioprocessing, including equipment and ‌consumables ⁠used to make biologic drugs, remained strong, with orders rising by a mid-teens percentage in the quarter, although customer project timing weighed on revenue.

"Assuming demand is not falling off a cliff this badly and ​this is just a ​push-out issue, ⁠we would think some of the weakness would get bought throughout the day for shares to close ​down," Barclays analysts said.

Danaher expects full-year adjusted per-share ​profit of $8.45 ⁠to $8.60, up from $8.35 to $8.55 previously. Analysts were expecting full-year adjusted profit of $8.45 per share.

The company posted second-quarter profit of $1.94 per share, above analysts' estimates ⁠of $1.83 ​per share. Revenue rose 5.5% to $6.27 billion, ​topping estimates of $6.10 billion.

Life sciences revenue increased 5.5% to $1.88 billion, above estimates of $1.80 billion.

Reporting ​by Sahil Pandey and Mariam Sunny in Bengaluru; Editing by Sahal Muhammed

Our Standards: The Thomson Reuters Trust Principles., opens new tab

, /PRNewswire/ -- Danaher Corporation (NYSE: DHR) today announced results for the second quarter 2026. All results in this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted.

Key Second Quarter 2026 Results

Net earnings were $870 million, or $1.23 per diluted common share, up 60% year-over-year. Non-GAAP adjusted diluted net earnings per common share grew 8.0% to $1.94. Revenues increased 5.5% year-over-year to $6.3 billion. Non-GAAP core revenue increased 3.0% year-over-year and non-GAAP core revenue excluding respiratory testing revenue increased 4.5% year-over-year. Operating cash flow was $1.5 billion and non-GAAP free cash flow was $1.3 billion. Strong Q2 earnings performance and earlier-than-anticipated completion of Masimo acquisition enabling increased full year 2026 adjusted diluted net earnings per common share guidance. Rainer M. Blair, President and Chief Executive Officer, stated, "We delivered a better than expected second quarter, with core growth improving versus the first quarter and disciplined execution driving high-single-digits adjusted EPS growth. Our Life Sciences businesses delivered their strongest quarter in several years and while customer project timing impacted bioprocessing revenue, underlying order trends remained strong and bioprocessing orders grew mid-teens in the quarter."

Mr. Blair continued, "Looking ahead, continued end-market recovery and traction from our recent growth initiatives support our expectation to exit 2026 at a mid-single-digit core revenue growth rate. Longer term, Danaher's leading portfolio, capital deployment optionality and talented team — all powered by the Danaher Business System — position us to accelerate the impact of science and technology, help customers move from discovery to delivery faster, and create sustainable long-term shareholder value."

Third Quarter and Full Year 2026 Outlook

Danaher Corporation (the "Company") does not reconcile non-GAAP forecasted core sales growth, adjusted operating profit margin and adjusted diluted net earnings per common share to their respective, comparable measure prepared in accordance with U.S. generally accepted accounting principles (GAAP) because (except for estimated amortization of acquisition-related intangible assets of $0.5 billion for the third quarter and $1.9 billion for the year ending December 31, 2026 and the estimated impact of foreign currency on sales, which is estimated to decrease sales by 1.0% in the third quarter and increase sales by 0.5% in the full year, assuming the currency exchange rates in effect as of June 26, 2026) the additional elements that would be reflected in any such GAAP measures (such as the impact of currency exchange rates on profitability, future acquisitions, divested product lines, discrete tax adjustments, impairments, gains and losses on investments and the outcome of legal proceedings) are difficult to predict and estimate and are often dependent on future events that may be uncertain or outside of our control. The impact of these additional elements could be material to our results computed in accordance with GAAP.

For the third quarter 2026, the Company anticipates that non-GAAP core revenue will increase in the 2.0% to 3.0% range year-over-year.

For full year 2026, the Company expects non-GAAP core revenue will increase in the 3.0% to 4.0% range year-over-year. The Company is also increasing its full year adjusted diluted net earnings per common share guidance to a range of $8.45 to $8.60 versus previous guidance of $8.35 to $8.55.

Conference Call and Webcast Information

Danaher will discuss its second quarter results and financial guidance for the third quarter and full year 2026, including as applicable key assumptions with respect thereto, during its investor conference call today starting at 8:00 a.m. ET. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available in the same section of Danaher's website shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.

The conference call can be accessed by dialing 833-419-0865, within the U.S. or +1 785-838-9333 outside the U.S. a few minutes before 8:00 a.m. ET and notifying the operator that you are dialing in for Danaher's earnings conference call (Conference ID: DHRQ226). A replay of the conference call will be available shortly after the conclusion of the call and until August 4, 2026. You can access the replay dial-in information on the "Investors" section of Danaher's website under the subheading "Events & Presentations."

ABOUT DANAHER

Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve their most complex scientific and clinical challenges—helping move innovations from discovery to delivery faster for patients who depend on them.

Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow. Explore more at www.danaher.com.

NON-GAAP MEASURES AND SUPPLEMENTAL MATERIALS

In addition to the financial measures prepared in accordance with GAAP, this earnings release also contains non-GAAP financial measures. Calculations of these measures, explanations of what these measures represent and the reasons why we believe these measures provide useful information to investors, a reconciliation of these measures to the most directly comparable GAAP measures, where applicable, and other information relating to these non-GAAP measures are included in the supplemental reconciliation schedule attached.

In addition, this earnings release, the slide presentation accompanying the related earnings call, non-GAAP reconciliations and a note containing details of historical and anticipated, future financial performance have been posted to the "Investors" section of Danaher's website (www.danaher.com).

FORWARD-LOOKING STATEMENTS AND OTHER INFORMATION

Statements in this release that are not strictly historical, including the statements regarding the Company's anticipated financial results for the third quarter and full year 2026, the Company's expectations regarding growth and market recovery, the Company's positioning to create long-term shareholder value, and any other statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things: the impact of the tariffs and related actions implemented by the U.S. and other countries, the impact of our debt obligations (including debt we incurred to finance the acquisition of Masimo Corporation) on our operations and liquidity, deterioration of or instability in the global economy, the markets we serve and the financial markets, uncertainties with respect to the development, deployment, and use of artificial intelligence in our business and products, the impact of global health crises, uncertainties relating to national laws or policies, including laws or policies to protect or promote domestic interests and/or address foreign competition, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated growth, synergies and other benefits of such acquisitions, contingent liabilities and other risks relating to acquisitions, investments, strategic relationships and divestitures (in each case, including with respect to our acquisition of Masimo Corporation), including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the health care industry, security breaches or other disruptions of our information technology systems or violations of data privacy laws, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation, regulatory proceedings and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States government with respect to our production capacity in times of national emergency or with respect to intellectual property/production capacity developed using government funding, risks relating to product, service or software defects, product liability and recalls, risks relating to our manufacturing operations, the impact of climate change, legal or regulatory measures to address climate change and other sustainability topics and our ability to address regulatory requirements or stakeholder expectations relating to climate change and other sustainability topics, risks relating to fluctuations in the cost and availability of the supplies we use (including commodities) and labor we need for our operations, our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties, the impact of deregulation on demand for our products and services, labor matters and our ability to recruit, retain and motivate talented employees, U.S. and non-U.S. economic, political, geopolitical, legal, compliance, social and business factors (including the impact of elections, regulatory and policy changes or uncertainty, government shutdowns and military conflicts such as the conflict in the Middle East), disruptions and other impacts relating to man-made and natural disasters, inflation and the impact of our By-law exclusive forum provisions. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2025 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the second quarter of 2026. These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

This press release may include descriptions of certain products and/or devices that have applications submitted and pending for certain regulatory approvals, or are available only in certain markets.

DANAHER CORPORATION AND SUBSIDIARIES

CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS

($ and shares in millions, except per share amounts)

(unaudited)

Three-Month Period Ended

Six-Month Period Ended

June 26, 2026

June 27, 2025

June 26, 2026

June 27, 2025

Sales

$           6,265

$           5,936

$          12,216

$          11,677

Cost of sales

(2,654)

(2,413)

(5,014)

(4,643)

Gross profit

3,611

3,523

7,202

7,034

Operating costs:

Selling, general and administrative expenses     

(2,072)

(2,360)

(3,932)

(4,218)

Research and development expenses

(412)

(403)

(799)

(782)

Operating profit

1,127

760

2,471

2,034

Nonoperating income (expense):

Other income (expense), net

(3)

(42)

(76)

(121)

Interest expense

(107)

(71)

(170)

(143)

Interest income

61

8

88

14

Earnings before income taxes

1,078

655

2,313

1,784

Income taxes

(208)

(100)

(414)

(275)

Net earnings

$              870

$              555

$           1,899

$           1,509

Net earnings per common share:

Basic

$             1.23

$             0.77

$             2.69

(a)

$             2.11

(a)

Diluted

$             1.23

$             0.77

$             2.68

$             2.10

(a)

Average common stock and common
equivalent shares outstanding:

Basic

705.3

716.5

706.6

716.4

Diluted

707.6

719.1

709.4

719.9

(a) Net earnings per common share amounts for the relevant three-month periods do not add to the six-month period amount due to rounding.

This information is presented for reference only. A complete copy of Danaher's Form 10-Q financial statements is available on the Company's website (www.danaher.com).

Diluted Net Earnings Per Common Share and Adjusted Diluted Net Earnings Per Common Share 

Three-Month Period Ended

Six-Month Period Ended

June 26, 2026

June 27, 2025

June 26, 2026

June 27, 2025

Diluted Net Earnings Per Common Share     
(GAAP)

$             1.23

$             0.77

$             2.68

$             2.10

Amortization of acquisition-related
intangible assets A

0.65

0.59

1.26

1.16

Fair value net (gains) losses on
investments B

0.01

0.06

0.12

0.19

Acquisition-related items C

0.15

—

0.18

—

Impairments D

—

0.60

—

0.62

Gain on a product line disposition E

—

—

—

(0.01)

Tax effect of the above adjustments F

(0.13)

(0.26)

(0.27)

(0.39)

Discrete tax adjustments G

0.03

0.03

0.03

0.02

Rounding

—

0.01

—

(0.01)

Adjusted Diluted Net Earnings Per
Common Share (Non-GAAP)

$             1.94

$             1.80

$             4.00

$             3.68

Notes to Reconciliation of GAAP to Non-GAAP Financial Measures

A

Amortization of acquisition-related intangible assets in the following historical periods ($ in millions) (only the pretax amounts set forth below are reflected in the amortization line item above):

Three-Month Period Ended

Six-Month Period Ended

June 26, 2026

June 27, 2025

June 26, 2026

June 27, 2025

Pretax

$              463

$              426

$              897

$              836

After-tax     

384

354

744

694

B 

Net (gains) losses on the Company's equity and limited partnership investments recorded in the following historical periods ($ in millions) (only the pretax amounts set forth below are reflected in the fair value net (gains) losses on investments line above):

Three-Month Period Ended

Six-Month Period Ended

June 26, 2026

June 27, 2025

June 26, 2026

June 27, 2025

Pretax

$                 7

$               44

$               84

$              134

After-tax     

5

33

64

101

C 

Fair value adjustments to inventory, transaction costs deemed significant and pre-acquisition share-based and change-in-control payments, in each case related to the acquisition of Masimo Corporation ("Masimo") in the three and six-month periods ended June 26, 2026 ($108 million and $125 million pretax as reported in this line item, $95 million and $110 million after-tax). The Company deems acquisition-related transaction costs incurred in a given period to be significant (generally relating to the Company's larger acquisitions) if it determines that such costs exceed the range of acquisition-related transaction costs typical for Danaher in a given period.

D 

Impairment charges related to a trade name in the Life Sciences segment recorded in the three and six-month periods ended June 27, 2025 ($432 million pretax as reported in this line item, $328 million after-tax) and a facility in the Biotechnology segment recorded in the six-month period ended June 27, 2025 ($15 million pretax as reported in this line item, $11 million after-tax).

E 

Gain on a product line disposition in the six-month period ended June 27, 2025 ($9 million pretax as reported in this line item, $7 million after-tax).

F 

This line item reflects the aggregate tax effect of all nontax adjustments reflected in the preceding line items of the table. In addition, the footnotes above indicate the after-tax amount of each individual adjustment item. Danaher estimates the tax effect of each adjustment item by applying Danaher's overall estimated effective tax rate to the pretax amount, unless the nature of the item and/or the tax jurisdiction in which the item has been recorded requires application of a specific tax rate or tax treatment, in which case the tax effect of such item is estimated by applying such specific tax rate or tax treatment.

G 

Discrete tax adjustments and other tax-related adjustments for both the three and six-month periods ended June 26, 2026, include the impact of net discrete tax charges of $21 million related primarily to changes in estimates associated with prior period uncertain tax positions, partially offset by benefits from the release of reserves for uncertain tax positions resulting from audit settlements and the expiration of statutes of limitations during the six-month period. Discrete tax adjustments and other tax-related adjustments for the three-month period ended June 27, 2025, include the impact of net discrete tax charges of $22 million related primarily to changes in uncertain tax positions and other items. Discrete tax adjustments and other tax-related adjustments for the six-month period ended June 27, 2025, include the impact of net discrete tax charges of $12 million related primarily to the release of reserves for uncertain tax positions due to the expiration of statutes of limitations, partially offset by changes in uncertain tax positions and other items.

Sales Growth by Segment, Core Sales Growth (Decline) by Segment and Core Sales Growth Excluding Respiratory Testing

% Change Three-Month Period Ended June 26, 2026 vs. Comparable 2025 Period

Segments

Total Company

Biotechnology

Life Sciences

Diagnostics

Total sales growth (GAAP)

5.5 %

4.0 %

5.5 %

7.0 %

Impact of:

Acquisitions

(1.5) %

— %

— %

(4.0) %

Currency exchange rates

(1.0) %

(1.5) %

— %

(1.0) %

Core sales growth (non-GAAP)

3.0 %

2.5 %

5.5 %

2.0 %

Impact of respiratory testing

1.5 %

3.0 %

Core sales growth excluding respiratory
testing (non-GAAP)     

4.5 %

5.0 %

% Change Six-Month Period Ended June 26, 2026 vs. Comparable 2025 Period

Segments

Total Company

Biotechnology

Life Sciences

Diagnostics

Total sales growth (GAAP)

4.5 %

7.5 %

4.5 %

2.5 %

Impact of:

Acquisitions

(0.5) %

— %

— %

(2.0) %

Currency exchange rates

(2.0) %

(3.0) %

(1.5) %

(1.5) %

Core sales growth (decline) (non-GAAP)

2.0 %

4.5 %

3.0 %

(1.0) %

Impact of respiratory testing

2.0 %

5.0 %

Core sales growth excluding respiratory
testing (non-GAAP)

4.0 %

4.0 %

Note: Beginning with the Company's Quarterly Report on Form 10-Q for the second quarter of 2026, in addition to disclosing core sales growth, the Company is disclosing a new non-GAAP measure, titled "Core sales growth excluding respiratory testing." This new measure adjusts core sales to exclude revenues related to the sale of respiratory testing products in the Company's molecular diagnostics business in the Diagnostics segment. Demand for respiratory testing depends significantly on the severity levels of influenza and influenza-like illness in a given period, and these severity levels are not under management's control. As a result, presenting core sales on a basis that combines respiratory testing revenue with other Diagnostics business revenues can obscure underlying growth trends within the Diagnostics businesses.  The Company believes that presenting this additional measure will complement core sales, enhance investors' understanding of the historical and anticipated performance of the Diagnostics businesses and Danaher as a whole, including with respect to underlying growth trends, and facilitate comparisons of period-to-period performance. In addition, beginning with the Company's Quarterly Report on Form 10-Q for the third quarter of 2026, the Company intends to exclude from the core sales measures the impact, if any, of tariff refunds (related to tariff payments made in prior periods) that are returned, or expected to be returned, to customers. The Company believes this adjustment will help investors better understand underlying growth trends in the Company's business that otherwise may be obscured by the above-noted tariff-related impacts.

Non-GAAP Forward-Looking Information

% Change Three-
Month Period Ending
September 25, 2026
vs. Comparable 2025
Period

% Change Three-
Month Period Ending
December 31, 2026
vs. Comparable 2025
Period

% Change Year
Ending December 31,
2026 vs. Comparable
2025 Period

Core sales growth (non-GAAP)

Biotechnology

+Mid-single digit

+Mid-single digit

Life Sciences

+3.0% - +4.0%

+3.0% - +4.0%

Diagnostics

Flat

+Up slightly

Total Company

+2.0% - +3.0%

+Mid-single digit

+3.0% - +4.0%

Impact of respiratory testing

+2.5 %

Flat

+Low-single digit

Core sales growth excluding respiratory testing (non-GAAP)     

~+5.0%

+Mid-single digit

+Mid-single digit

Three-Month Period
Ending

September 25, 2026

Year Ending

December 31, 2026

Adjusted operating profit margin (non-GAAP)

 ~26.5  %

Adjusted diluted net earnings per common share (non-GAAP)

$8.45 - $8.60

Other Forward-Looking Information

Three-Month Period
Ending

September 25, 2026

Year Ending

December 31, 2026

Impact of currency exchange rates on sales H

~(1.0)%

~+0.5%

Amortization of acquisition-related intangible assets ($ in millions)     

~$(500)

~$(1,900)

Corporate expense I ($ in millions)

~$(90)

~$(360)

Interest expense, net J ($ in millions)

~$(115)

~$(310)

Effective tax rate

 ~17.0  %

 ~17.0  %

Average adjusted diluted shares (in millions)

~707

~709

H 

Impact of currency exchange rates on sales for the second quarter and full year 2026 assumes the currency exchange rates in effect as of June 26, 2026.

I 

Corporate expense represents the operating profit (GAAP) for the Other segment, which consists of unallocated corporate costs and other costs not considered part of management's evaluation of reportable segment operating performance.

J  

Interest expense, net is defined as interest expense net of interest income. This line item is an assumption rather than a forecast. The estimated interest expense, net is calculated assuming the currency exchange rates in effect as of June 26, 2026 are to prevail throughout the remainder of the period indicated and no change in the amount of commercial paper outstanding.

Pending SLMP LLC "StatLab" Acquisition

Earlier this month, Leica Biosystems, our anatomic pathology business, announced their intention to acquire StatLab, a leading manufacturer of products across the core histology workflow, from specimen collection through slide staining. The business has >85% recurring revenue and is complementary to Leica Biosystems' existing oncology instrument portfolio.

Below is some information on StatLab:

StatLab generated ~$250M in revenue for the full year 2025 The Company expects StatLab to have +high-single digit core sales growth over the long term The Company expects StatLab to be accretive to Adjusted diluted net earnings per common share (non-GAAP) in the 1st full year of ownership The Company expects to close this acquisition by the end of 2026, subject to customary closing conditions and regulatory approvals Historical Sales (Decline) Growth, Core Sales Growth and Core Sales Growth Excluding Respiratory Testing

% Change Three-Month Period Ended vs. Comparable 2024 Period

% Change Year
Ended
December 31,
2025 vs.
Comparable
2024 Period

% Change
Three-Month
Period Ended
March 27, 2026
vs. Comparable
2025 Period

March 28, 2025

June 27, 2025

September 26,
2025

December 31,
2025

Total sales (decline) growth
(GAAP)

(1.0) %

3.5 %

4.5 %

4.5 %

3.0 %

3.5 %

Impact of:

Acquisitions/divestitures

(0.5) %

— %

— %

0.5 %

— %

— %

Currency exchange rates

1.5 %

(2.0) %

(1.5) %

(2.5) %

(1.0) %

(3.0) %

Core sales growth (non-GAAP)

— %

1.5 %

3.0 %

2.5 %

2.0 %

0.5 %

Impact of respiratory testing

1.0 %

0.5 %

(0.5) %

1.5 %

0.5 %

2.5 %

Core sales growth excluding
respiratory testing (non-GAAP)     

1.0 %

2.0 %

2.5 %

4.0 %

2.5 %

3.0 %

Note: For the impact of respiratory testing, a positive amount represents a year-over-year headwind to core sales growth, and a negative amount represents a year-over-year tailwind to core sales growth.

Historical and Forward-Looking Respiratory Testing Sales

($ in millions)

 Three-Month Period Ended

Year
Ended
December
31, 2025 K

Three-Month Period
Ended

Three-Month Period
Ending

Year
Ending
December
31, 2026 K

March 28,
2025

June 27,
2025

September
26, 2025

December
31, 2025

March 27,
2026

June 26,
2026

September
25, 2026

December
31, 2026

Respiratory     
testing
sales L

~$650

~$300

~$500

~$500

~$1,900

~$500

~$250

~$325

~$500

~$1,600

K

Respiratory testing sales amounts for the relevant three-month periods may not add to the year-to-date period amount due to rounding.

L

Actual respiratory testing sales are rounded to the nearest $50 million.

Cash Flow and Free Cash Flow

($ in millions)

Three-Month Period Ended

Year-over-
Year Change

Six-Month Period Ended

Year-over-
Year Change

June 26, 2026

June 27, 2025

June 26, 2026

June 27, 2025

Total Cash Flow:

Net cash provided by
operating activities
(GAAP)

$            1,534

$           1,338

$           2,856

$           2,637

Total cash used in
investing activities
(GAAP)

$         (10,147)

$             (258)

$        (10,396)

$            (500)

Total cash provided by
(used in) financing
activities (GAAP)

$            7,273

$             (247)

$           7,319

$         (1,502)

Free Cash Flow:

Net cash provided by
operating activities
(GAAP)

$            1,534

$           1,338

 ~ 14.5 %

$           2,856

$           2,637

 ~ 8.5   %

Less: payments for
additions to property, plant     
& equipment (capital
expenditures) (GAAP)     

(269)

(248)

(506)

(493)

Plus: proceeds from sales
of property, plant &
equipment (capital
disposals) (GAAP)

—

4

—

10

Free cash flow (non-
GAAP)

$            1,265

$           1,094

 ~ 15.5 %

$           2,350

$           2,154

 ~ 9.0   %

Operating Cash Flow to
Net Earnings
Conversion Ratio:

Net cash provided by
operating activities
(GAAP)

$            1,534

$           1,338

$           2,856

$           2,637

Net earnings (GAAP)

870

555

1,899

1,509

Operating cash flow to net
earnings conversion ratio
(GAAP)

1.76

2.41

1.50

1.75

Free Cash Flow to Net
Earnings Conversion
Ratio:

Free cash flow from
above (non-GAAP)

$            1,265

$           1,094

$           2,350

$           2,154

Net earnings (GAAP)

870

555

1,899

1,509

Free cash flow to net
earnings conversion ratio
(non-GAAP)

1.45

1.97

1.24

1.43

We define free cash flow as operating cash flows, less payments for additions to property, plant and equipment ("capital expenditures") plus the proceeds from sales of plant, property and equipment ("capital disposals"). 

Statement Regarding Non-GAAP Measures

Each of the non-GAAP measures set forth above should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measure, and may not be comparable to similarly titled measures reported by other companies. Management believes that these measures provide useful information to investors by offering additional ways of viewing Danaher Corporation's ("Danaher" or the "Company") results that, when reconciled to the corresponding GAAP measure, help our investors:

with respect to the profitability-related non-GAAP measures, understand the long-term profitability trends of our business and compare our profitability to prior and future periods and to our peers; with respect to the non-GAAP measures related to core sales, identify underlying growth trends in our business and compare our sales performance with prior and future periods and to our peers; and with respect to free cash flow (the "FCF Measure"), understand Danaher's ability to generate cash without external financings, strengthen its balance sheet, invest in its business and grow its business through acquisitions and other strategic opportunities (although a limitation of free cash flow is that it does not take into account the Company's debt service requirements and other non-discretionary expenditures, and as a result the entire free cash flow amount is not necessarily available for discretionary expenditures). Management uses the non-GAAP measures referenced above to measure the Company's operating and financial performance, and uses core sales and non-GAAP measures similar to Adjusted Diluted Net Earnings Per Common Share, Adjusted Operating Profit and the FCF Measure in the Company's executive compensation program.

The items excluded from the non-GAAP measures set forth above have been excluded for the following reasons:

With respect to the profitability-related non-GAAP measures: Amortization of Intangible Assets: We exclude the amortization of acquisition-related intangible assets because the amount and timing of such charges are significantly impacted by the timing, size, number and nature of the acquisitions we consummate. While we have a history of significant acquisition activity we do not acquire businesses on a predictable cycle, and the amount of an acquisition's purchase price allocated to intangible assets and the related amortization term are unique to each acquisition and can vary significantly from acquisition to acquisition. Exclusion of this amortization expense facilitates more consistent comparisons of operating results over time between our newly acquired and long-held businesses, and with both acquisitive and non-acquisitive peer companies. We believe however that it is important for investors to understand that such intangible assets contribute to sales generation and that intangible asset amortization related to past acquisitions will recur in future periods until such intangible assets have been fully amortized. Restructuring Charges: We exclude costs incurred pursuant to discrete restructuring plans that are fundamentally different (in terms of the size, strategic nature and planning requirements, as well as the inconsistent frequency, of such plans) from the ongoing productivity improvements that result from application of the Danaher Business System. Because these restructuring plans are incremental to the core activities that arise in the ordinary course of our business and we believe are not indicative of Danaher's ongoing operating costs in a given period, we exclude these costs to facilitate a more consistent comparison of operating results over time. Other Adjustments: With respect to the other items excluded from the profitability-related non-GAAP measures, we exclude these items because they are of a nature and/or size that occur with inconsistent frequency, occur for reasons that may be unrelated to Danaher's commercial performance during the period and/or we believe that such items may obscure underlying business trends and make comparisons of long-term performance difficult.  With respect to core sales, (1) we exclude the impact of currency translation because it is not under management's control, is subject to volatility and can obscure underlying business trends, and (2) we exclude the effect of acquisitions and divested product lines because the timing, size, number and nature of such transactions can vary significantly from period-to-period and between us and our peers, which we believe may obscure underlying business trends and make comparisons of long-term performance difficult. Please see "Sales Growth by Segment, Core Sales Growth (Decline) by Segment and Core Sales Growth Excluding Respiratory Testing" above for an explanation on why we exclude respiratory testing revenues from the non-GAAP measure "Core sales excluding respiratory testing". In addition, beginning with the Company's Quarterly Report on Form 10-Q in the third quarter of 2026, the Company intends to exclude from core sales the impact of tariff refunds related to prior period tariffs that are returned, or expected to be returned, if any, to customers as the Company believes these amounts may obscure underlying business trends.  With respect to the FCF Measure, we deduct payments for additions to property, plant and equipment (net of the proceeds from capital disposals) to demonstrate the amount of operating cash flow for the period that remains after accounting for the Company's capital expenditure requirements. SOURCE Danaher Corporation

Posted by Defense World Staff on Jul 20th, 2026

Broderick Brian C grew its position in shares of Danaher Corporation (NYSE:DHR – Free Report) by 4.4% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 65,605 shares of the conglomerate’s stock after purchasing an additional 2,794 shares during the quarter. Danaher makes up about 2.3% of Broderick Brian C’s portfolio, making the stock its 16th biggest holding. Broderick Brian C’s holdings in Danaher were worth $12,439,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in DHR. Main Street Group LTD purchased a new position in Danaher in the first quarter valued at $25,000. JPL Wealth Management LLC purchased a new stake in shares of Danaher during the 3rd quarter worth about $25,000. Elevated Capital Advisors LLC purchased a new stake in shares of Danaher during the 4th quarter worth about $26,000. WFA of San Diego LLC acquired a new stake in shares of Danaher during the 2nd quarter valued at about $26,000. Finally, Hilton Head Capital Partners LLC acquired a new stake in shares of Danaher during the 4th quarter valued at about $27,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Stock Down 0.1% DHR stock opened at $203.65 on Monday. Danaher Corporation has a 52 week low of $160.93 and a 52 week high of $242.80. The company has a quick ratio of 1.52, a current ratio of 1.87 and a debt-to-equity ratio of 0.33. The firm has a 50-day simple moving average of $183.27 and a 200-day simple moving average of $198.25. The stock has a market capitalization of $144.14 billion, a P/E ratio of 39.39, a P/E/G ratio of 2.51 and a beta of 0.79.

Danaher (NYSE:DHR – Get Free Report) last issued its quarterly earnings results on Monday, April 20th. The conglomerate reported $2.06 earnings per share for the quarter, beating analysts’ consensus estimates of $1.94 by $0.12. Danaher had a net margin of 14.89% and a return on equity of 10.91%. The firm had revenue of $5.95 billion for the quarter, compared to analyst estimates of $6 billion. During the same period last year, the company posted $1.88 EPS. Danaher’s quarterly revenue was up 3.7% compared to the same quarter last year. Equities analysts forecast that Danaher Corporation will post 8.45 earnings per share for the current fiscal year.

Danaher Dividend Announcement The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Friday, June 26th will be given a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 0.8%. The ex-dividend date is Friday, June 26th. Danaher’s dividend payout ratio (DPR) is 30.95%.

Analyst Upgrades and Downgrades DHR has been the subject of a number of analyst reports. The Goldman Sachs Group reduced their price target on Danaher from $265.00 to $230.00 and set a “buy” rating for the company in a report on Monday, April 13th. JPMorgan Chase & Co. dropped their price objective on Danaher from $275.00 to $245.00 and set an “overweight” rating on the stock in a report on Wednesday, April 22nd. Evercore restated an “outperform” rating and issued a $230.00 price objective on shares of Danaher in a research report on Monday, July 6th. UBS Group reduced their target price on Danaher from $270.00 to $250.00 and set a “buy” rating for the company in a research note on Wednesday, April 22nd. Finally, Wall Street Zen lowered Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, Danaher presently has an average rating of “Moderate Buy” and an average target price of $231.64.

Read Our Latest Report on DHR

Danaher Profile (Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.

Read More Five stocks we like better than Danaher Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit Shopify’s Quiet AI Strategy Could Be Its Biggest Advantage Yet Why These 3 Nuclear ETFs Are Getting a Fresh Look as AI Power Demand Rises 3 Aerospace Suppliers That Could Benefit as Aircraft Makers Face Bottlenecks Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR – Free Report).

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEBroderick Brian C Purchases 1,454 Shares of Vertex Pharmaceuticals Incorporated $VRTX

NEXT HEADLINE »Decker Wealth Management LLC Purchases New Stake in Newmont Corporation $NEM

Key Takeaways Danaher is expected to report Q2 revenues of $6.08 billion, up 2.4% year over year.DHR's Biotechnology segment is projected to grow 5.5%, supported by bioprocessing demand.Danaher's Masimo acquisition expanded its diagnostics portfolio, while costs and debt remain headwinds. Danaher Corporation (DHR - Free Report) is scheduled to release second-quarter 2026 results on July 21, before market open.

The Zacks Consensus Estimate for revenues is pegged at $6.09 billion, which indicates an increase of 2.6% from the year-ago quarter’s figure. The consensus mark for earnings is pinned at $1.84 per share, which has increased a penny in the past seven days. The estimate indicates an increase of 2.2% from the figure reported in the year-ago quarter. The company’s bottom line surpassed the Zacks Consensus Estimate in each of the preceding four quarters, the average beat being 6.7%.

Let’s see how things have shaped up for Danaher this earnings season.

Key Factors and Estimates for Q2Strength in the bioprocessing business, driven by an increase in demand for consumables from large pharmaceutical customers in Western Europe and China, is expected to have aided the Biotechnology segment. The segment’s performance is also likely to have benefited from solid momentum in the medical filtration and research consumables business. For the second quarter, the Zacks Consensus Estimate for the segment’s total sales is pegged at $1.95 billion, indicating a 5.5% rise from the year-ago reported number.

Strength in the clinical diagnostics businesses, led by growth in clinical lab and pathology diagnostics units, is expected to drive the Diagnostics segment’s results. However, softness in the molecular diagnostics business due to sluggish demand for respiratory tests is likely to have been a spoilsport. For the second quarter, the Zacks Consensus Estimate for the segment’s total sales is pegged at $2.33 billion, indicating a 0.7% rise from the year-ago reported number.

Solid momentum in filtration and consumables businesses is likely to have boosted the performance of the Life Sciences segment in the quarter. For the second quarter, the Zacks Consensus Estimate for the segment’s total sales is pegged at $1.79 billion, indicating a 0.8% rise from the year-ago reported number.

In June 2026, Danaher acquired Masimo Corp. for $9.9 billion. The addition of Masimo’s advanced sensor technology and AI-enabled monitoring enabled Danaher to enhance its diagnostics portfolio. The buyout is expected to have boosted DHR’s performance during the quarter.

However, the escalating costs and operating expenses, due to increasing input costs and product mix changes, are likely to have weighed on DHR’s bottom line in the to-be-reported quarter. Also, higher interest expenses associated with the company’s high debt are likely to prove detrimental to its profitability in the quarter.

Earnings WhispersOur proven model predicts an earnings beat for DHR this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is the case here, as elaborated below.

Earnings ESP: Danaher has an Earnings ESP of +0.62% as the Most Accurate Estimate is pegged at $1.85 per share, which is higher than the Zacks Consensus Estimate of $1.84. You can uncover the best stocks before they’re reported with our Earnings ESP Filter.

Zacks Rank: DHR currently carries a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank stocks here.

Other Stocks to ConsiderHere are some other companies within the broader Medical sector, which according to our model, have the right combination of elements to beat on earnings in this reporting cycle.

Cardinal Health (CAH - Free Report) has an Earnings ESP of +1.24% and a Zacks Rank of 2 at present. The company is slated to release fourth-quarter fiscal 2026 results on Aug. 11.

Cardinal Health’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 10.3%.

CVS Health (CVS - Free Report) has an Earnings ESP of +1.42% and a Zacks Rank of 2 at present. The company is scheduled to release second-quarter 2026 results on Aug. 5.

CVS Health’s earnings surpassed the Zacks Consensus Estimate in each of the preceding four quarters, the average surprise being 16.8%.

West Pharmaceutical Services (WST - Free Report) has an Earnings ESP of +1.09% and a Zacks Rank of 2 at present. The company is slated to release second-quarter 2026 results on July 23.

West Pharmaceutical’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 19.4%.

Wall Street analysts forecast that Danaher (DHR - Free Report) will report quarterly earnings of $1.84 per share in its upcoming release, pointing to a year-over-year increase of 2.2%. It is anticipated that revenues will amount to $6.09 billion, exhibiting an increase of 2.6% compared to the year-ago quarter.

Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.2% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.

Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.

While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.

That said, let's delve into the average estimates of some Danaher metrics that Wall Street analysts commonly model and monitor.

It is projected by analysts that the 'Total Sales- Diagnostics' will reach $2.33 billion. The estimate points to a change of +0.8% from the year-ago quarter.

According to the collective judgment of analysts, 'Total Sales- Life Sciences' should come in at $1.79 billion. The estimate indicates a year-over-year change of +0.9%.

The average prediction of analysts places 'Total Sales- Biotechnology' at $1.95 billion. The estimate indicates a change of +5.5% from the prior-year quarter.

The consensus among analysts is that 'Operating profit- Biotechnology' will reach $574.60 million. Compared to the present estimate, the company reported $531.00 million in the same quarter last year.

The consensus estimate for 'Operating profit- Diagnostics' stands at $521.81 million. Compared to the current estimate, the company reported $554.00 million in the same quarter of the previous year.

View all Key Company Metrics for Danaher here>>>

Danaher shares have witnessed a change of +13% in the past month, in contrast to the Zacks S&P 500 composite's +0.5% move. With a Zacks Rank #2 (Buy), DHR is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Wall Street expects a year-over-year increase in earnings on higher revenues when Danaher (DHR - Free Report) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.

The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on July 21. On the other hand, if they miss, the stock may move lower.

While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.

Zacks Consensus EstimateThis industrial and medical device maker is expected to post quarterly earnings of $1.83 per share in its upcoming report, which represents a year-over-year change of +1.7%.

Revenues are expected to be $6.08 billion, up 2.4% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 0.38% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for Danaher?For Danaher, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -0.07%.

On the other hand, the stock currently carries a Zacks Rank of #2.

So, this combination makes it difficult to conclusively predict that Danaher will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that Danaher would post earnings of $1.94 per share when it actually produced earnings of $2.06, delivering a surprise of +6.19%.

Over the last four quarters, the company has beaten consensus EPS estimates four times.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

Danaher doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

Key Takeaways Danaher's Biotechnology segment grew 7% in Q1 2026, driven by strong bioprocessing demand. DHR's bioprocessing equipment orders rose more than 30% on solid pharmaceutical demand. Danaher expects Biotechnology growth despite weaker filtration, consumables and equipment demand. Danaher Corporation’s (DHR - Free Report) Biotechnology segment continues to be a major contributor to its growth. In the first quarter of 2026, the segment’s core revenues increased 7% on a year-over-year basis, driven by strength in the bioprocessing business. On a geographical basis, higher sales in Western Europe and China fueled the increase in core sales.

The bioprocessing business is benefiting from higher demand for consumables from large pharmaceutical customers. Also, solid demand from pharmaceutical customers for monoclonal antibodies (mAbs) has been aiding the business. In the first quarter of 2026, orders for bioprocessing equipment increased more than 30%. For 2026, Danaher expects core revenues from the bioprocessing business to rise in high single digits on a year-over-year basis. Also, strength in the medical filtration and research consumables business bodes well for the Biotechnology segment.

However, the Biotechnology segment is facing headwinds due to weak demand for medical filtration products and research consumables in the discovery and medical business. Lower equipment demand is also weighing on the segment's performance.

Despite these headwinds, Danaher expects the Biotechnology segment’s core revenues to grow in the mid-single digits year over year in the second quarter of 2026. Rising demand for bioprocessing products is expected to support the segment’s performance in the coming quarters.

Segment Snapshot of DHR's PeersAmong its major peers, Labcorp Holdings Inc.’s (LH - Free Report) Biopharma Laboratory Services segment generated net sales of $780.6 million in the first quarter of 2026, up 8.2% year over year. This was driven by Labcorp’s strong drug development capabilities and scientific expertise. Labcorp derived 22.1% of its total revenues from this segment during the quarter.

Its another peer: CVS Health Corporation’s (CVS - Free Report) Health Services segment reported net sales of $48.24 billion in the first quarter of 2026, up 11% year over year. CVS Health generated 48% of its total sales from this segment in the quarter. Favorable pharmacy drug mix and brand inflation aided the segment’s results in the second quarter.

DHR's Price Performance, Valuation and EstimatesShares of Danaher have gained 3% in the past month compared with the industry’s growth of 7.1%.

Image Source: Zacks Investment Research

From a valuation standpoint, DHR is trading at a forward price-to-earnings ratio of 22.08X, above the industry’s average of 16.51X.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for DHR’s 2026 earnings has increased a penny over the past 30 days.

Image Source: Zacks Investment Research

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Shareholders should contact the firm immediately as there may be limited time to enforce your rights. 

, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Danaher Corporation (NYSE: DHR) breached their fiduciary duties to shareholders.

If you currently own Danaher stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected].

Why Your Participation Matters:

Shareholder involvement can help improve a company's policies, practices, and oversight mechanisms to create a more transparent, accountable, and effectively managed organization, which can enhance shareholder value.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLC
One World Trade Center
85th Floor
New York, NY 10007
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com

SOURCE Halper Sadeh LLP

Danaher (DHR - Free Report) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, DHR crossed above the 20-day moving average, suggesting a short-term bullish trend.

A well-liked tool among traders, the 20-day simple moving average offers a look back at a stock's price over a 20-day period. This is very beneficial to short-term traders, as it smooths out short-term price trends and gives more trend reversal signals than longer-term moving averages.

The 20-day moving average can show signals that are similar to other SMAs as well. If a stock's price is moving above the 20-day, the trend is considered positive. When the price falls below the moving average, it can signal a downward trend.

Shares of DHR have been moving higher over the past four weeks, up 9.1%. Plus, the company is currently a Zacks Rank #3 (Hold) stock, suggesting that DHR could be poised for a continued surge.

Looking at DHR's earnings estimate revisions, investors will be even more convinced of the bullish uptrend. There have been 1 revisions higher for the current fiscal year compared to none lower, and the consensus estimate has moved up as well.

Investors should think about putting DHR on their watchlist given the ultra-important technical indicator and positive move in earnings estimate revisions.

, /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2026 on Tuesday, July 21, 2026 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations.

The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.

You can access the conference call by dialing 833-419-0865, within the U.S. or +1 785-838-9333 outside the U.S. a few minutes before 8:00 a.m. ET and notifying the operator that you are dialing in for Danaher's earnings conference call (Conference ID: DHRQ226). A replay of the conference call will be available shortly after the conclusion of the call until August 4, 2026. You can access the replay dial-in information on the "Investors" section of Danaher's website under the subheading "Events & Presentations."

Danaher's earnings press release, the webcast slides and other related materials will be posted to the "Investors" section of Danaher's website under the subheading "Quarterly Earnings" beginning at 6:00 a.m. ET on the date of the earnings call and will remain available following the call.

ABOUT DANAHER
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve many of their most complex scientific and clinical challenges—helping move innovations from discovery to delivery faster for patients who depend on them.

Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow. Explore more at www.danaher.com.

SOURCE Danaher Corporation

, /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Bank of America Securities Health Care Conference in Las Vegas, Nevada on Wednesday, May 13, 2026 at 11:20 a.m. PT. The event will be simultaneously webcast on www.danaher.com.

ABOUT DANAHER
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve many of their most complex scientific and clinical challenges—helping move innovations from discovery to delivery faster for patients who depend on them.

Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow. Explore more at www.danaher.com.

SOURCE Danaher Corporation

Key Takeaways DHR's Biotechnology segment posted 7% core revenue growth in Q1 2026, led by bioprocessing.Danaher saw bioprocessing equipment orders rise more than 30% amid strong pharma demand for mAbs.DHR expects Biotechnology core revenues to rise mid-single digits in Q2 2026 despite headwinds. Danaher Corporation (DHR - Free Report) continues to benefit from strength in its Biotechnology segment. In the first quarter of 2026, the segment’s core revenues increased 7% on a year-over-year basis, supported by sustained momentum in the bioprocessing business. Geographically, the increase in core sales was driven by higher sales in Western Europe and China.

An increase in demand for consumables from large pharmaceutical customers has been aiding the performance of the Biotechnology segment. Also, solid demand from pharmaceutical customers for monoclonal antibodies (mAbs) has been buoying the bioprocessing business. In the first quarter of 2026, orders for bioprocessing equipment increased more than 30%. For 2026, Danaher anticipates core revenues from the bioprocessing business to increase in high single-digits on a year-over-year basis. Also, strength in the medical filtration and research consumables business bodes well for the Biotechnology segment.

However, lower demand for medical filtration and research consumables in the discovery and medical business is concerning for the Biotechnology segment. Declining demand for equipment is also acting as a headwind for it.

Despite these challenges, for the second quarter of 2026, Danaher anticipates core revenues from the Biotechnology segment to increase in mid-single digits on a year-over-year basis. Consistent demand for products within the bioprocessing business is expected to support stable segment performance in the coming quarters.

Segment Snapshot of DHR's PeersAmong its major peers, CVS Health Corporation’s (CVS - Free Report) Health Services segment reported net sales of $48.24 billion in the first quarter of 2026, up 11% year over year. CVS Health generated 48% of its total sales from this segment in the quarter. Favorable pharmacy drug mix and brand inflation aided the segment’s results in the second quarter.

Labcorp Holdings Inc.’s (LH - Free Report) Biopharma Laboratory Services segment generated net sales of $780.6 million in the first quarter of 2026, up 8.2% year over year. This was driven by Labcorp’s strong drug development capabilities and scientific expertise. Labcorp derived 22.1% of its total revenues from this segment during the quarter.

DHR's Price Performance, Valuation and EstimatesShares of Danaher have declined 26.5% in the past six months compared with the industry’s decrease of 10.9%.

Image Source: Zacks Investment Research

From a valuation standpoint, DHR is trading at a forward price-to-earnings ratio of 19.22X, above the industry’s average of 14.51X.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for DHR’s 2026 earnings has increased over the past 30 days.

Image Source: Zacks Investment Research

The company currently carries a Zacks Rank #3 (Hold).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Barron's Oil & Blue Chip Tips for May 2026 highlight 20 stocks, with 11 deemed 'safer' based on free cash flow yields exceeding dividend yields. Top ten by yield are projected to deliver average net gains of 36.08% by May 2027, with risk/volatility 24% below the market average. Zoetis (ZTS), Danaher (DHR), and Accenture (ACN) lead in projected returns, with ZTS estimated to net 60.33% and lower-than-market volatility.

MARLBOROUGH, Mass.--(BUSINESS WIRE)--At ASMS, SCIEX, a Danaher company and leader in life science analytical technologies, launched the novus V55 system - a next-generation triple quadrupole mass spectrometer designed for the realities of high-pressure, results-driven labs. The system provides exceptional sensitivity and accelerated output, in a smaller footprint and with improved energy efficiency when compared to the SCIEX 5500+ system. This quantitative solution expands testing capabilities across pesticide and food analysis, pharmaceutical impurities, bioanalysis, PFAS testing and additional applications.

The novus V55 system is built for business and real-world impact. Key features include:

aeMRM (accelerated MRM) can acquire up to 1,000 MRMs per second, which increases sample throughput, expands testing capabilities, and maintains quantitative accuracy. New SCIEX OS 5.0 software introduces new features including: Central Metrics Tracker allows for tracking of performance and assay level metrics. Central Monitoring shows instrument status across the fleet. Reporter Template Creator easily creates customized reports. AI enabled “helpme” function answers feature and functionality questions quickly using a natural language interface. AI enabled Calculated Columns creates custom calculations for columns with natural language. OptiFlow source, built off the same technology trusted by thousands of customers world-wide, upholds the robustness and sensitivity synonymous with SCIEX systems. 35% smaller footprint makes it the most compact triple quad in its class without compromising sensitivity or quantitative performance. 40% reduction in both energy consumption and laboratory cooling requirements helps to lower operational energy costs. Compatibility with any LC system, LIMS support, and 21 CFR Part 11 maintains compliance and operational confidence. “Analytical labs are being asked to deliver more insight with less time, space, and energy. With the novus V55 system, we have applied decades of innovation to ensure robustness and sensitivity, while enhancing performance and execution. This new generational instrument will help enable our customers to drive their business forward,” says Chris Lock, Vice President Global Research and Development at SCIEX.

This 5th generation system builds on a proven legacy in nominal mass. In 1981, SCIEX launched the TAGA 6000, the first commercial triple quadrupole. Since then, the triple quadrupoles have evolved with the API III, then the API 4000, and then to the SCIEX Triple Quad series starting with SCIEX Triple Quad 5500 system. SCIEX also developed QTRAP technology which combined triple quad and linear ion trap technology for the first time.

Learn more about the novus V55 system at https://sciex.com/products/mass-spectrometers/triple-quad-systems/novus-v55-system.

ABOUT SCIEX

SCIEX, a Danaher company and leader in life science analytical technologies, empowers our customers to solve the most impactful analytical challenges in quantitation and characterization. With groundbreaking innovation and outstanding reliability and support, SCIEX has been at the forefront of the field for over 50 years. ​

Since the launch of the first-ever commercially successful triple quadrupole in 1981, we continue to develop technologies and solutions that influence life-changing research and outcomes. That’s why thousands of life science experts around the world choose SCIEX to get the answers they can trust. ​

Advances in human wellness depend on the power of precise science.​

For more information, visit sciex.com. ​

Connect with us on LinkedIn, Facebook, and Instagram.​

ABOUT DANAHER

Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve their most complex scientific and clinical challenges—helping move innovations from discovery to delivery faster for patients who depend on them. Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow. Explore more at www.danaher.com.

The SCIEX clinical diagnostic portfolio is for in vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to www.sciex.com/diagnostics. All other products are For Research Use Only. Not for use in Diagnostic Procedures.

Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries (see www.sciex.com/trademarks).

© 2026 DH Tech. Dev. Pte. Ltd. MKT-38491-A.

, /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a global science and technology innovator, announced today that it has completed the acquisition of Masimo Corporation, a leading specialty diagnostics provider of pulse oximetry and other patient monitoring solutions, primarily in acute care treatment settings.

Masimo's trusted brand, advanced sensor technology and AI-enabled patient monitoring bring complementary and powerful new capabilities to the Danaher diagnostics portfolio. As a result of the transaction, Masimo is now a wholly-owned subsidiary of Danaher and Masimo common stock has ceased trading on the Nasdaq Stock Market. Masimo will continue to operate under the Masimo brand and will be a stand-alone operating company within Danaher's Diagnostics segment.

"Masimo is a strong strategic fit for Danaher. Together, we expect to strengthen our ability to deliver differentiated products in acute care settings and accelerate Masimo's growth and global reach," said Julie Sawyer Montgomery, Executive Vice President of Diagnostics at Danaher. "We are excited to welcome the Masimo team to Danaher."

The consideration payable to former Masimo stockholders will be paid in accordance with the terms of the merger agreement, as further described in the definitive transaction materials filed with the U.S. Securities and Exchange Commission.

Second Quarter and Full Year 2026 Outlook

There is no change to Danaher's previously communicated second quarter and full-year 2026 guidance range, excluding the expected contribution from Masimo. The Company does not expect a material contribution from Masimo in the second quarter of 2026. The Company intends to update full-year 2026 guidance in connection with its second quarter earnings release to incorporate Masimo's expected contribution.

FORWARD-LOOKING STATEMENTS AND OTHER INFORMATION
Statements in this release that are not strictly historical, including the statements regarding the Company's anticipated financial results for the second quarter and full year 2026, expected strengthening of the Company's ability to deliver differentiated products in acute care settings, expected acceleration of Masimo's growth and global reach, and any other statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws.  There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements.  These factors include, among other things: the impact of the tariffs and related actions implemented by the U.S. and other countries, the impact of our debt obligations (including debt we have incurred to finance the acquisition of Masimo Corporation) on our operations and liquidity, deterioration of or instability in the global economy, the markets we serve and the financial markets, uncertainties with respect to the development, deployment, and use of artificial intelligence in our business and products, the impact of global health crises, uncertainties relating to national laws or policies, including laws or policies to protect or promote domestic interests and/or address foreign competition, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated growth, synergies and other benefits of such acquisitions, contingent liabilities and other risks relating to acquisitions, investments, strategic relationships and divestitures (in each case, including with respect to our acquisition of Masimo), including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the health care industry, security breaches or other disruptions of our information technology systems or violations of data privacy laws, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation, regulatory proceedings and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States government with respect to our production capacity in times of national emergency or with respect to intellectual property/production capacity developed using government funding, risks relating to product, service or software defects, product liability and recalls, risks relating to our manufacturing operations, the impact of climate change, legal or regulatory measures to address climate change and other sustainability topics and our ability to address regulatory requirements or stakeholder expectations relating to climate change and other sustainability topics, risks relating to fluctuations in the cost and availability of the supplies we use (including commodities) and labor we need for our operations, our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties, the impact of deregulation on demand for our products and services, labor matters and our ability to recruit, retain and motivate talented employees, U.S. and non-U.S. economic, political, geopolitical, legal, compliance, social and business factors (including the impact of elections, regulatory and policy changes or uncertainty, government shutdowns and  military conflicts such as the conflict in the Middle East), disruptions and other impacts relating to man-made and natural disasters, inflation and the impact of our By-law exclusive forum provisions.  Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2025 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the first quarter of 2026.  These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

ABOUT DANAHER
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve many of their most complex scientific and clinical challenges—helping move innovations from discovery to delivery faster for patients who depend on them. Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow. Explore more at www.danaher.com.

SOURCE Danaher Corporation

Investors in Danaher Corporation (DHR - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the June 18, 2026 $145 Call had some of the highest implied volatility of all equity options today.

What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.

What do the Analysts Think?Clearly, options traders are pricing in a big move for Danaher shares, but what is the fundamental picture for the company? Currently, Danaher is a Zacks Rank #3 (Hold) in the Medical Services industry that ranks in the Top 43% of our Zacks Industry Rank. Over the last 60 days, no analyst increased the earnings estimates for the current quarter, while seven have dropped their estimates. The net effect has taken our Zacks Consensus Estimate for the current quarter from $1.89 per share to $1.84 in that period.

Given the way analysts feel about Danaher right now, this huge implied volatility could mean there’s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.